Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 9 recruiting now early-phase tilt

Cannabis: early-phase trial registry

9 of 25 indexed Cannabis trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #652 of 28,707 conditions by registered trial count.

25 US clinical trials · 9 currently recruiting · #652 of 28,707 conditions by registered trial count

Cannabis: 25 US clinical trials tracked, 9 recruiting.

Cannabis is the subject of 25 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is Yale University, running 8 of these trials.

Enrollment posture brief

Registry condition cannabis

OPEN 9 | RECR 36% | LATE 0 | EARLY 15 | RANK #652 | SPON 8

Nearest open-share peer: Cytomegalovirus Infections (36% recruiting · 25 trials)

Alpha-1 Antitrypsin Deficien48%Alcohol Use40%Acute Lymphocytic Leukemia36%Alcohol-Related Disorders36%Cannabis (this)36%
Open-enrollment share among volume-matched conditions near Cannabis

Cannabis lists 9 open slots (36% of 25 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Cannabis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Cannabis is recruiting below its size-band peers.

    9 of 25 indexed trials (36%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Cannabis research.

    Yale University accounts for 8 of 25 trials (32%). 15 distinct sponsors appear on at least one study for this condition label.

  3. Most Cannabis trials plan to enrol fewer than 100 people.

    Median target enrolment is 48 among the 25 trials that report a genuine target (sentinel values excluded). 18 of those (72%) plan for fewer than 100 participants.

  4. Cannabis research is mostly interventional.

    23 interventional and 2 observational studies make up this index (92% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 110Phase 25

Open and recent trials

25 total, page 1 of 1

RECRUITING Phase 2 350 participants

Cannabis' Impact on Alcohol Consumption

Brown University

NCT05389930

RECRUITING 320 participants

Cannabis, HIV and Mental Processing Systems

Washington University School of Medicine

NCT05430490

RECRUITING NA 220 participants

Modeling the Effects of Chronic Marijuana Use on Neuroinflammation and HIV-related Neuronal Injury

Wake Forest University Health Sciences

NCT04810858

RECRUITING Phase 1 100 participants

Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans

Yale University

NCT02781519

RECRUITING Phase 1 100 participants

Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II

Yale University

NCT04704271

RECRUITING Phase 2 90 participants

Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV

University of California, San Diego

NCT05514899

RECRUITING 64 participants

Cannabis Observations on Brain Waves, Retrieval, and Attention: Experiment 3

L. Cinnamon Bidwell

NCT06669585

RECRUITING Phase 2 48 participants

Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration

University of California, San Francisco

NCT05999383

RECRUITING Phase 1 40 participants

Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study I

Yale University

NCT02811510

ACTIVE NOT RECRUITING Phase 1 80 participants

Cannabinoids, Learning, and Memory

Yale University

NCT02407808

ACTIVE NOT RECRUITING Phase 1 40 participants

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study II

Yale University

NCT02710097

ACTIVE NOT RECRUITING Phase 1 40 participants

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition

Yale University

NCT02404688

ACTIVE NOT RECRUITING Phase 1 40 participants

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Substudy III

Yale University

NCT02710331

ACTIVE NOT RECRUITING Phase 1 40 participants

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study I

Yale University

NCT02709954

ACTIVE NOT RECRUITING Phase 1 20 participants

THC Memory & Reward Learning Pilot

Hartford Hospital

NCT05116527

COMPLETED NA 448 participants

Intervening to Prevent Youth Access to Marijuana Phase II

Klein Buendel

NCT03073291

COMPLETED NA 361 participants

Web-based vs In-person Personalized Feedback Intervention for Comorbid Substance Use and Disordered Gambling

University of Washington

NCT01529047

COMPLETED Phase 2 92 participants

Efficacy of Inhaled Cannabis for Acute Migraine Treatment

University of California, San Diego

NCT04360044

COMPLETED NA 60 participants

Impact of Reduced Cannabis Use on Functional Outcomes (R33 Phase)

Duke University

NCT04567238

COMPLETED NA 35 participants

Pain Inflammation and Cannabis in HIV

Montefiore Medical Center

NCT05554146

COMPLETED NA 29 participants

Families With Substance Use and Psychosis: A Pilot Study

Mclean Hospital

NCT04284813

COMPLETED NA 25 participants

Impact of Reduced Cannabis Use on Functional Outcomes

Duke University

NCT03681353

COMPLETED Phase 1 8 participants

Laboratory Smoking of Marijuana "Blunts"

Battelle Memorial Institute

NCT03546790

COMPLETED Phase 2 5 participants

Effect of Cannabis and Endocannabinoids on HIV Neuropathic Pain

University of California, San Diego

NCT03099005

COMPLETED NA 3 participants

Feasibility Trial of rTMS for Cannabis Use Disorder

Medical University of South Carolina

NCT03538288

Phase Distribution

PhaseTrial count
Phase 1 10
Phase 2 5

Named interventions

Most-linked intervention names on Cannabis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
9 trials
THC Drug
3 trials
Active Ethanol Drug
2 trials
Active Oral Ethanol Drug
2 trials
Cannabis Drug
2 trials
Mobile Contingency Management, active Behavioral
1 trials
Receipt of Coupon for High CBD Soft-Gel Capsule Other
1 trials
Receipt of Coupon for Equal THC and CBD Soft-Gel Capsule Other
1 trials

US sites by state

Facility locations filed on Cannabis trials. A trial with sites in several states counts in each.

Connecticut 9 trials
California 5 trials
North Carolina 3 trials
Colorado 2 trials
Washington 1 trials
South Carolina 1 trials
Rhode Island 1 trials
New York 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Cannabis page

25 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cannabis condition card totals 25 registered trials; most-linked intervention Placebo; top US site state Connecticut. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.